These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17913044)

  • 1. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
    Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
    Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
    Mayer LD; Harasym TO; Tardi PG; Harasym NL; Shew CR; Johnstone SA; Ramsay EC; Bally MB; Janoff AS
    Mol Cancer Ther; 2006 Jul; 5(7):1854-63. PubMed ID: 16891472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
    Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
    Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.
    Tardi PG; Dos Santos N; Harasym TO; Johnstone SA; Zisman N; Tsang AW; Bermudes DG; Mayer LD
    Mol Cancer Ther; 2009 Aug; 8(8):2266-75. PubMed ID: 19671743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
    Dicko A; Frazier AA; Liboiron BD; Hinderliter A; Ellena JF; Xie X; Cho C; Weber T; Tardi PG; Cabral-Lilly D; Cafiso DS; Mayer LD
    Pharm Res; 2008 Jul; 25(7):1702-13. PubMed ID: 18320294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
    Batist G; Gelmon KA; Chi KN; Miller WH; Chia SK; Mayer LD; Swenson CE; Janoff AS; Louie AC
    Clin Cancer Res; 2009 Jan; 15(2):692-700. PubMed ID: 19147776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
    Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
    J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety.
    Franco MS; Oliveira MC
    Anticancer Agents Med Chem; 2019; 19(1):17-28. PubMed ID: 29692263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
    Lim WS; Tardi PG; Xie X; Fan M; Huang R; Ciofani T; Harasym TO; Mayer LD
    Leuk Lymphoma; 2010 Aug; 51(8):1536-42. PubMed ID: 20528246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
    Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
    Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
    Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
    Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
    Harasym TO; Liboiron BD; Mayer LD
    Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
    Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
    BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
    Iwase Y; Maitani Y
    Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.